Impact Of Somatic Mutations On Outcome In Patients > 60 Years Old With Newly Diagnosed Aml Treated With Response-Adapted Sequential Azacitidine And Induction Chemotherapy Within The Drks00004519 Trial (Ras-Azic) Of The East German Study Group Of Hematology And Oncology (Osho)

Introduction: Old age and unfavorable cytogenetics are well-established adverse prognostic factors for outcome in patients (pts) with AML. Recently, high-throughput sequencing techniques have identified multiple somatically acquired driver mutations (muts) with a strong prognostic impact in AML. We explored the relative contribution of baseline molecular genetics versus a response-based sequential treatment approach on response and overall survival (OS) at two years in pts >60 years (y) with newly diagnosed AML treated within the multicenter RAS-AZIC study of the OSHO.